MMPX hioUTP tetrasodium salt Safinamide has been approved by

Safinamide has been approved by the European Medicines Agency for the treatment of adult patients with idiopathic Parkinson’s disease as add-on therapy to a stable dose of Levodopa (L-dopa) alone or in combination with other PD drugs in patients with mid-to-late-stage fluctuating disease

3)4)63-48(68)14-11-9-7-6-8-10-12-15-49(69)65-25-23-64(24-26-65)22-13-27-73-47-30-41-44(31-46(47)72-5)59-34-60-52(41)62-39-20-21-43(57)42(56)28-39/h16-21

functions optimally in acidic conditions

5-250 μg/kg

Chemical Name: 5-(4-butoxy-3-chlorophenyl)-N-{[2-(morpholin-4-yl)pyridin-3-yl]methyl}pyridine-3-carboxamide

MMPX hioUTP tetrasodium salt Safinamide has been approved byProduct information CAS Number: 78033 08 6 Molecular Weight: 266. 30 Formula: C12H18N4O3 Chemical Name: 8 (methoxymethyl) 1 methyl 3 (2 methylpropyl) 2,3,6,7 tetrahydro 1H purine 2,6 dione Smiles: CN1C(=O)N(CC(C)C)C2N=C(COC)NC=2C1=O InChiKey: NBLBCGUCPBXKOV UHFFFAOYSA N InChi: InChI=1S C12H18N4O3 c1 7(2)5 16 10 9(11(17)15(3)12(16)18)13 8(14 10)6 19 4 h7H,5 6H2,1 4H3,(H,13,14) Technical Data Appearance: Solid Power Purity: 98% (or refer to the